Influvac Tetra – Seasonal Flu Vaccine Protection

Influvac Tetra is a quadrivalent influenza vaccine used to protect individuals against seasonal flu (influenza). The vaccine is designed to protect against four strains of the influenza virus, including two influenza A subtypes (H1N1 and H3N2) and two influenza B strains. Influvac Tetra is made from inactivated (killed) viruses, which stimulate the immune system to produce antibodies without causing illness. It is typically administered as an intramuscular flu shot and is recommended for individuals 6 months of age and older.

Pharmaceutical Properties of Influvac Tetra

Formulation
Influvac Tetra is a sterile suspension for injection, commonly provided in pre-filled syringes or vials.

Components

• Inactivated influenza A virus strains (H1N1 and H3N2)

• Inactivated influenza B virus strains (two lineages)

• No live virus is used in the vaccine formulation.

Adjuvants
This flu vaccine does not contain adjuvants, as its inactivated components are sufficient to generate a protective immune response.

Storage Conditions
The vaccine for influenza prevention should be stored between 2°C and 8°C. Do not freeze.

Shelf Life
The shelf life of Influvac Tetra is generally between 12 and 24 months, depending on storage and manufacturing details.

Indications for Use

Primary Prevention of Influenza
Influvac Tetra is indicated for active immunization against influenza in individuals aged 6 months and older. It is designed to protect against multiple flu strains during the flu season.

Vulnerable Populations
This seasonal influenza vaccine is especially recommended for:

• People with chronic illnesses (e.g., diabetes, asthma, heart disease)

• Seniors aged 65 and older

• Pregnant women (all trimesters)

• Healthcare workers and caregivers

Post-Exposure Prophylaxis
In select cases, Influvac Tetra may be used after potential exposure to the flu virus to reduce severity, although it is primarily used for flu prevention.

Mechanism of Action

Influvac Tetra introduces inactivated influenza virus antigens to the body. These antigens trigger the production of antibodies without causing the flu.

• Influenza A protection: H1N1 and H3N2 strains induce targeted immune responses.

• Influenza B coverage: The two B strains ensure broad immunity during flu outbreaks.

Vaccination allows the immune system to rapidly recognize and combat the influenza virus, reducing illness severity. Since flu viruses mutate seasonally, annual flu vaccination is recommended.

Clinical Protocol in Dubai

As per Dubai Health Authority (DHA) guidelines, Influvac Tetra flu vaccine is administered with the following protocol:

Administration Schedule

• Annual vaccination: One dose is given before flu season (usually in fall).

• Children (6 months–8 years): May require two doses their first year, spaced 4 weeks apart.

• Adults (9+ years): Only one dose per year is required.

Post-Vaccination Monitoring
Observe for 15 minutes after administration. Common flu vaccine side effects include:

• Mild injection site pain or redness

• Fatigue

• Low-grade fever

Contraindications
Do not administer to individuals with severe allergies to vaccine components, especially egg proteins. Avoid in those with past Guillain-Barré syndrome following a flu vaccine.

Special Considerations
Pregnant and breastfeeding women can receive the vaccine, but should consult a healthcare provider first.

Additional Characteristics

Storage: 2°C to 8°C (do not freeze)
Shelf Life: 12–24 months depending on the batch
Adverse Effects: Generally mild; any severe reactions should be reported to a doctor

Conclusion

Influvac Tetra is a highly effective flu vaccine that offers broad protection against seasonal influenza. Covering four virus strains, it is a crucial tool in preventing flu-related complications, especially in high-risk groups such as young children, the elderly, and people with chronic illnesses. In Dubai, it plays a central role in the annual flu vaccination program, helping reduce the public health impact of influenza.